Free Trial
LON:APH

Alliance Pharma 4/8/2025 Earnings Report

Alliance Pharma logo
GBX 64.60 0.00 (0.00%)
As of 12:14 PM Eastern

Alliance Pharma EPS Results

Actual EPS
GBX 4.32
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Alliance Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alliance Pharma Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Alliance Pharma Earnings Headlines

RBC Capital Reaffirms Their Hold Rating on Alliance Pharma (APH)
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
See More Alliance Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alliance Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alliance Pharma and other key companies, straight to your email.

About Alliance Pharma

Alliance Pharma (LON:APH) operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

View Alliance Pharma Profile

More Earnings Resources from MarketBeat